Side-by-side · Research reference

5-Amino-1MQvsPNC-27

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongAUTO-DRAFTED8/38 cited

BAnimal-StrongHUMAN-REVIEWED18/41 cited

5-Amino-1MQ

NNMT inhibitor · Methylation / SAM modulation

100–200 mgDaily dose (oral)Neelakantan 2018

AnimalEvidence levelNeelakantan 2018

HoursHalf-life (est)

Oral · Once daily fasted

PNC-27

p53-HDM-2 Peptide · Membrane-Targeting

32 AAPeptide lengthSarafraz-Yazdi 2022

12-26p53 domain

Pre-clinicalDevelopment stage

In vitro / Pre-clinical only

01Mechanism of Action

Parameter

5-Amino-1MQ

PNC-27

Primary target

Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018

Membrane-bound HDM-2 protein on cancer cell surfaceSarafraz-Yazdi 2022 Krzesaj 2024

Pathway

NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018

PNC-27 binds to membrane HDM-2 1-109 domain → transmembrane pore formation → rapid necrosis (poptosis)Pincus 2024 Krzesaj 2024

Downstream effect

Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018

Immediate cell lysis and extrusion of intracellular contents; secondary mitochondrial membrane disruptionPincus 2024 Krzesaj 2024

Feedback intact?

—

N/A — cytotoxic mechanism, not signaling modulation

Origin

Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018

Chimeric design: p53 transactivating domain (12-26) fused to penetratin CPP sequenceSarafraz-Yazdi 2022

Antibody development

—

02Dosage Protocols

Parameter

5-Amino-1MQ

PNC-27

Standard dose

100–200 mg / day oralNeelakantan 2018

Anecdotal community range; murine doses scaled.

—

Frequency

Once daily, fasted

—

Lower / starter dose

50 mg / day

—

Evidence basis

Animal-strong; no human RCT dataNeelakantan 2018

Pre-clinical / In vitro

Duration

8–12 weeks per cycle

—

Form

Oral capsule

—

Timing

Morning fasted preferred

—

Half-life

Hours (estimated; no human PK published)

—

Clinical status

—

Pre-clinical only — no human trials

In vitro and animal model data only.

In vitro concentrations

—

10–100 μM range

Effective concentrations in cell culture studies.

Shorter analogue

—

PNC-28 (28 AA variant)

Retains HDM-2 binding and cytotoxic activity.

03Metabolic / Fat Loss Evidence

Parameter

5-Amino-1MQ

PNC-27

Fat loss mechanism

—

None — cytotoxic anticancer agent

04Side Effects & Safety

Parameter

5-Amino-1MQ

PNC-27

GI symptoms

Mild nausea (anecdotal)

—

Methylation disruption

Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)

—

Long-term safety

Unknown — no human trials

—

Cancer risk

Unclear — NNMT also studied in oncology contexts

—

Pregnancy / OB

Avoid

—

Drug interactions

Theoretical with niacin / B-vitamin supplements

—

Human safety data

—

None available — no human trials conducted

Normal cell selectivity

—

In vitro: no cytotoxicity to normal cells (MCF-10-2A, peripheral blood mononuclear cells)Sarafraz-Yazdi 2010 Thadi 2020

Normal cells express minimal membrane HDM-2.

Cancer cell specificity

—

Depends on membrane HDM-2 expression levels

Ovarian cancer lines with low membrane HDM-2 showed <30% necrosis.

Cell death mechanism

—

Necrosis (not apoptosis) — rapid membrane lysisPincus 2024

Mitochondrial effects

—

Secondary mitochondrial membrane disruption in cancer cells

Absolute Contraindications

5-Amino-1MQ

·Pregnancy / breastfeeding
·Active malignancy

PNC-27

·Human use — no clinical trials or safety data

Relative Contraindications

5-Amino-1MQ

·Methylation-sensitive conditions (MTHFR mutation)
·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)

PNC-27

—

05Administration Protocol

Parameter

5-Amino-1MQ

PNC-27

1. Form

Oral capsule. No injection.

PNC-27 has not been tested in human subjects. All data derive from in vitro cancer cell line studies and limited animal models. No approved clinical formulation, dosing protocol, or safety profile exists.Pincus 2024

2. Administration

Take with water, fasted preferred.

In vitro studies used 10–100 μM PNC-27 dissolved in cell culture medium. Peptide was added directly to cancer cell cultures (pancreatic, breast, colon, ovarian, leukemia lines) and incubated for 24–72 hours.

3. Timing

Morning fasted.

Dual-labeled PNC-27 (green on N-terminus, red on C-terminus) demonstrated intact peptide binding to cancer cell membranes with combined yellow fluorescence at 30 minutes, persisting during cell lysis.Sookraj 2010

4. Storage

Room temp ≤25 °C, dry place.

Cytotoxicity correlates directly with membrane HDM-2 expression levels. Blocking HDM-2's p53-binding domain (1-109) with monoclonal antibodies prevents PNC-27-induced necrosis.

5. Caveat

Monitor B-vitamin status with chronic use.

—